The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins.